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Abstract: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor 
of the gastrointestinal tract. In advanced setting and after progression to imatinib, the multi-
targeted receptor tyrosine kinase inhibitor sunitinib has clearly demonstrated a clinical benefit 
in terms of response rate and progression-free survival with an acceptable toxicity profile. The 
recommended schedule for sunitinib administration is 50 mg per day 4 weeks ON and 2 weeks 
OFF; however, potential alternative schedules are also reviewed in the present article. Several 
biomarkers have been explored to better select candidates for sunitinib therapy, such as the 
value of early changes in standardized uptake value assessed by positron emission tomography 
with 18F-fluorodeoxyglucose, circulating biomarkers, clinical biomarkers such as the appearance 
of arterial hypertension during treatment that correlates with better outcomes, and the GIST 
genotype. GISTs with KIT mutations at exon 9 and the so-called wild-type GISTs seem to better 
respond to sunitinib. Nonetheless, further investigation is required to confirm these findings as 
well as to understand the mechanisms of sunitinib resistance such as the development of new 
KIT mutations or conformational changes in KIT receptor.
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GIST: an overview
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the 
gastrointestinal tract. GISTs are more frequently found in stomach (~50%), followed 
by small intestine (25%), colon/rectum (5%–10%), and esophagus (5%).1 The mean 
age of presentation of GIST is between 50 and 70 years, although it can be diagnosed 
at any age.2
Surgical resection followed by adjuvant Imatinib mesylate (Glivec®; Novartis 
Pharma, Basel, Switzerland) in selected cases is the treatment of choice for GISTs. 
In metastatic setting (between 15% and 50% of patients develop metastases), GIST 
represents one of the paradigms of targeted agents era.3 Initially, median survival for 
patients with advanced disease was around 10–18 months because no effective thera-
pies were available.2 However, after discovering the role of stem cell factor receptor 
(KIT) gene mutations in the pathogenesis of GIST and the consequent introduction 
of KIT inhibitor imatinib in GIST treatment dramatically improved the prognosis of 
these patients.
The KIT, platelet-derived growth factor receptor alpha (PDGFRα) and ABL 
kinase inhibitor imatinib at doses of 400 mg daily until progression of disease and/or 
unacceptable toxicity is the standard first-line treatment in patients with unresectable 
and/or metastatic GIST. Imatinib was approved by Food and Drug Administration 
(FDA) after the results of a phase II trial in which .60% of patients experimented 
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partial responses (PRs) to imatinib and some of them 
maintained the benefit for a long period of time.4 Imatinib is 
supposed to be the first step in advanced GIST treatment, but 
further investigation is required given that between 10% and 
15% of GISTs are primary resistant to imatinib, 50% develop 
secondary resistance within 2 years of imatinib initiation 
and ~4% of GIST patients are intolerant to imatinib.5
Sunitinib malate (Sutent®; Pfizer, New York, NY, USA) 
was approved by regulatory entities after disease progression 
or intolerance to imatinib in 2006, which is the objective 
of this review. Recently, another multitargeted receptor 
tyrosine kinase inhibitor (TKI) regorafenib (Stirvarga; Bayer 
HealthCare Pharmaceuticals Inc; Montville, NJ, USA) has 
been approved after failure or intolerance to imatinib and 
sunitinib. The recommended dose is 160 mg taken orally 
once per day for the first 21 days of each 28-day cycle. 
After promising results of a phase II trial,6 the pivotal trial 
that leads to regorafenib approval was an international, 
randomized (2:1), placebo-controlled, multicenter phase III 
trial (the GRID one) that clearly showed improvement in 
progression-free survival (PFS), but not in overall survival 
(OS), probably because of the crossover design.7 Other 
agents for advanced GIST treatment, mostly TKIs, have 
been investigated unless they are not widespread used either 
because limited activity in trials or lack of enough data to 
recommend them. Masatinib, ponatinib, nilotinib, pazopanib, 
and sorafenib are some examples.
Pharmacologic profile of sunitinib
Mechanism of action
Sunitinib is a multi-targeted TKI with anti-tumor and anti-
angiogenic properties. Specifically, sunitinib is an inhibitor of 
vascular endothelial growth factor receptor (VEGFR) types 
1–3, PDGFRα and β, KIT, colony-stimulating factor type 1, 
glial cell-line-derived neurotrophic factor receptor (RET), 
and fetal liver tyrosine kinase receptor 3. Table 1 describes 
the half maximal inhibitory concentration of sunitinib for 
each tyrosine kinase receptor according to data obtained 
from several cell lines of solid tumors. As it is shown, suni-
tinib is a potent inhibitor of VEGFR1 and 3, as well as of 
PDGFR α/β.8
Pharmacological parameters
Sunitinib is primarily metabolized by cytochrome CYP3A4 
and as a result a pharmacologically active metabolite 
N-desethyl metabolite (SU012662) is formed, which is fur-
ther metabolized to inactive fraction. SU012662 is considered 
equipotent to the parent compound regarding the inhibition 
of VEGFR, PDGFR, and KIT. Both have large volume of 
distribution, indicating good tissue penetration. Table 2 
describes the pharmacokinetic parameters of both sunitinib 
and SU012662.9
Special situations
Theoretically, the pharmacokinetic profile is not altered by 
age, body mass index, gender, race, creatinine clearance, 
previous digestive tube resections, or performance status 
according to the Eastern Cooperative Oncology Group clas-
sification (ECOG). However, consistent data addressing these 
situations are probably lacking.
One of the main concerns when oral antineoplastic agents 
are administered is the drug absorption when patients have 
previously underwent resections of digestive tube. This issue 
is of special relevance in GIST patients, and it was assessed 
in a retrospective analysis of 305 individuals. The conclusion 
was that gastrectomy does not imply variations in sunitinib 
or SU012662 exposure, but it does if a small bowel resection 
has also been done in addition to gastrectomy (lower blood 
levels of sunitinib and SU012662), nonetheless without 
meaningful clinical relevance.10
Related with renal impairment, sunitinib seems to be 
safe and effective in patients with renal insufficiency, even 
in end-stage, although these studies have been done in 
renal carcinoma population and not in GIST ones.11 For 
mild or moderate hepatic alteration, no special precautions 
are needed for sunitinib dose, but increases or decreases in 
plasma drug concentration can occur if CYP3A4 inhibitors or 
Table 1 iC50 of sunitinib for different tyrosine kinase receptors








Abbreviations: FLT3, fetal liver tyrosine kinase receptor 3; iC50, half maximal 
inhibitory concentration; PDGFR, platelet-derived growth factor receptor; veGFR, 
vascular endothelial growth factor receptor.
Table 2 Pharmacokinetic parameters of sunitinib and SU012662
Parameter Sunitinib SU012662
Half-life 40 hours 80 hours
Time to plasma peak 4–6 hours 8–12 hours
Protein binging rate 95% 90%
excretion in feces 70%–84% Majority
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Sunitinib in GiST treatment
inducers, respectively, are concomitantly taken.12 Regarding 
body weight, it is important to consider that it has effects on 
clearance and distribution volume of sunitinib and SU12662. 
Although no dose adjustments are recommended by regula-
tory entities, individual analysis demonstrates that sunitinib 
plasma levels in patients with severe obesity can be below the 
required for drug activity at conventional sunitinib doses.13 
This issue is of special interest given that steady-state area 
under the curve of total drug (pharmacologically active at 
levels between 50 and 100 ng/mL) is correlated with patient 
outcome in terms of time to progression (TTP) and OS.14 
If fasting state can influence in sunitinib, pharmacokinetics 
has to be evaluated in a phase I trial with healthy volunteers, 
and it has been concluded that sunitinib can be taken either 
with or without food.15
Development of sunitinib in GIST: 
from bench to bedside
Preclinical data
Molecular mechanisms by sunitinib that exerts its antitumor 
function are not clearly elucidated, partly because available 
preclinical data are scarce. Preclinical studies with GIST 
cell lines suggest that SU11248 induces growth arrest and 
apoptosis of GIST cells. In addition, GIST cells exposition 
to SU11248 inhibits c-KIT autophosphorylation and the 
phosphorylation of AKT and ERK, key components of PI3K-
Akt-mTOR and MAPK pathways, respectively, involved in 
cell survival and proliferation. This fact provides a rational 
for combining sunitinib with other target therapies directed 
to the mentioned pathways.16
early trials
An open-label, single-arm, dose-escalation phase I/II trial 
in Western population enrolled 97 patients with metastatic 
GIST who have progressed to imatinib or they were intolerant 
to it.17 Several doses and schedules were tested in different 
cohorts in order to evaluate treatment safety: schedule 2/2 
(2 weeks ON sunitinib, 2 weeks OFF) at doses of 25, 50, or 
75 mg/day, and schedules 4/2 and 2/1 starting at 50 mg/day. 
The dose of 50 mg/day was defined as maximum tolerated 
dose because two of four patients treated at 75 mg/day 2/2 
experienced dose-limiting toxicities during the first cycle 
(fatigue, nausea, and vomiting). Pharmacokinetic analysis 
revealed that steady state was achieved by days 7–10 and 
7–21 for sunitinib and SU12662, respectively. In order to 
maximize sunitinib exposure, the schedule 4/2 was selected 
for further development. Promising sunitinib activity was 
observed in this trial since 54% of patients benefited from 
the treatment. More concisely, 7 patients presented PR with 
a median time of 8.3 months to achieve it and 45 patients 
experienced long-lasting stable disease (SD) for a minimum 
of 6 months. Median PFS was 7.8 months (95% confi-
dence interval [CI], 5.1–10.4 months), and median OS was 
19 months (95% CI, 12.9–21.5 months). Approximately 
60 participants of this trial had a baseline positron emission 
tomography with 18F-fluorodeoxyglucose (FDG-PET) and 
another on day 7 of cycle 1. Even if it will be detailed later, 
early metabolic responses correlated with better clinical 
outcomes.
In addition, sunitinib activity was also demonstrated in a 
preclinical setting because approximately half of the patients 
included had pre- and post-sunitinib biopsies. After 1 week 
of sunitinib treatment, levels of phospho-KIT in tumor 
samples as well as the expression of proteins involved in cell 
proliferation (cyclin A and AKT) in a percentage of patients 
were reduced. Mentioned early changes related to lower cell 
proliferation could correlate with better clinical outcomes, 
but it is a hypothesis to be further demonstrated.
Another phase I/II nonrandomized, open-label, and 
dose-escalating study aimed to evaluate the safety and 
preliminary efficacy of sunitinib in Asiatic population.18 
About 12 patients were enrolled in part I and doses of 25, 
50, and 75 mg/day of sunitinib on schedule 4/2 were tested; 
50 mg/day on schedule 4/2 until progression disease (PD) 
and/or unacceptable toxicity was defined as recommended 
phase II dose and after that several dose-limiting toxicities 
were observed in the cohort of 75 mg/day on schedule 4/2. 
A total of 36 patients were included in part II of the study and 
received the previously defined dose. According to Response 
Evaluation Criteria in Solid Tumors (RECIST), 11% of 
patients experiment a PR and, globally, the disease control 
rate was ~61%. Median TTP was 28.3 weeks. Regarding 
safety, all patients included experienced at least one adverse 
treatment-related event, but 84% of them were grade 1/2 and 
generally manageable and reversible.
A meta-analysis including GIST and renal cell carcinoma 
patients treated with sunitinib underlined the importance of 
maintaining sunitinib dosage and schedule. The achievement 
of the steady state of sunitinib and SU12662 correlated 
with better response rate, TTP, and OS, however, with the 
increased incidence of some adverse events (AEs) also.14
Pivotal and expanded access trials
After phase I/II trial, sunitinib efficacy was further demon-
strated in a phase III trial.19 This one was multicenter, random-
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had presented imatinib resistance or intolerance. A total of 
302 patients were randomly assigned 2:1 to receive sunitinib 
at doses established in phase I (n: 207) or placebo (n: 105). 
However, the trial was early unblinded due to the results of 
planned interim analysis that clearly favored sunitinib in 
terms of TTP. Median TTP in sunitinib arm was 27.3 weeks 
(95% CI 16.0–32.1) versus 6.4 weeks in placebo ones (95% 
CI 4.4–10.0; hazard ratio [HR] 0.33; 95% CI 0.23–0.47; 
P,0.0001). After these results, all patients treated with 
placebo were allowed to receive open-label sunitinib. OS 
data were more difficult to analyze because of the crossover. 
According to Kaplan–Meier method, OS did not reveal 
statistically significant differences between sunitinib and 
placebo (73.9 weeks versus 64.9 weeks; 95% CI 45.7–96.0; 
P=0.161). Nonetheless, a posterior long-term OS analysis 
was performed using another statistical method that accounts 
for the bias introduced by the crossover from placebo to suni-
tinib, the rank-preserving structural failure time (RPSFT). 
RPSFT method identified clear differences in median OS 
favoring sunitinib group (73.9 weeks; 95% CI 61.3–85.7 
versus 35.7 weeks; 95% CI 25.7–49.8; P,0.001).20
An expanded-access study for patients ineligible for pre-
vious trials or for whom sunitinib was unavailable enrolled 
1,126 patients who received sunitinib 50 mg/day 4/2 until 
PD and/or unacceptable toxicity.21 The results were better 
than pivotal trial, thus median TTP was 41.0 weeks (95% 
CI 36–47) and OS was ~75.0 weeks (95% CI 68–84). Sub-
group analyses were performed and age #65 years, prior ima-
tinib dose (400 mg daily or lower), and Eastern Cooperative 
Oncology Group performance status of one or less favored 
longer OS. Regarding elderly population ($65 years) who 
are usually under-represented in clinical trials, a retrospec-
tive French series of 71 patients showed similar benefit of 
sunitinib than in younger patients. However, dose reductions 
or interruptions were more frequent and often the comorbidi-
ties implied a higher risk of AE.22
Although the sound trials of sunitinib in GIST have mostly 
been performed in Western countries, retrospective series in 
both Taiwanese and Chinese population as well as a small 
prospective study in Chinese patients suggest similar efficacy 
and toxicity profile compared with Western population.23–25
Sunitinib safety
In general terms, sunitinib AEs are mild and reversible, but 
their optimal management is crucial in order to maintain 
patients on sunitinib therapy. In the pivotal phase III trial, 
the most common AEs were fatigue (47%), diarrhea (43%), 
nausea (36%), anorexia (28%), and dysgeusia (25%). 
However, most common grade 3–4 AEs were fatigue (10%), 
arterial hypertension (AH, 7%), and hand–foot syndrome 
(6%). Regarding hematological AEs, they were mainly 
grade 1–2 and consisted of hemoglobin, neutrophils, and 
platelet reductions. As a consequence of AEs, in 36% of 
patients dose interruptions were required and in 28% of 
patients dose reductions were required.19 The AE profile in 
the expanded-access study was very close to the observed 
one in the phase III.
As mentioned in the section “Patient selection for suni-
tinib therapy,” appearance of AH during sunitinib therapy has 
been postulated as a positive predictive biomarker of sunitinib 
response. However, it is also important to consider if AH 
induces higher risk of cardiovascular AE not only in GIST 
patients but also in renal cell carcinoma patients. This issue 
was evaluated in a retrospective series, and cardiovascular 
events seemed to be slightly more frequent in those patients 
with AH (5% of grade 3 cardiac events in patients with AH 
versus 3% in patients without AH). Nevertheless, mortality 
related with cardiac events in patients receiving sunitinib is 
very low.26–28
In addition, sunitinib can induce reductions in left ven-
tricular ejection function (LVEF), being $20% from basal 
level in ~2% of cases. Worsening a pre-existing AH and 
developing AH during sunitinib therapy are risk factors for 
LVEF impairment. In these patients and in those with other 
cardiac comorbidities, close monitoring of LVEF should 
be performed, despite cardiac failure related with sunitinib 
tends to be reversible after stopping the drug.29 The previous 
described findings come from analysis including renal and 
GIST patients. In the expanded use program limited to GIST 
patients, grade 3 or 4 heart failure, myocardial infarction or 
pulmonary edema were ,1%.30
No predictive biomarkers of sunitinib-related AH devel-
opment have been approved, although VEGF polymorphisms 
were evaluated as a putative biomarkers and the presence of 
VEGF-A rs699947 correlated with AH appearance during 
treatment in patients with renal cell cancer.31
Hypothyroidism is considered an AE clearly related to 
sunitinib, although it was not taken into consideration since 
the beginning. A prospective and an observational study with 
42 patients treated with sunitinib revealed abnormal serum 
thyroid-stimulating hormone in as much as 62% of partici-
pants. The biological explanation for this AE is that suntinib 
also inhibits ret proto-oncogene, and it binds to proteins 
that assemble with thyroid hormone receptor (for example, 
retinoid X receptor alpha and retinoic acid receptors beta and 
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Sunitinib in GiST treatment
and regular control of thyroid profile since the beginning of 
the therapy is mandatory. Its management is usually easy 
with hormone replacement that allows to continue sunitinib 
therapy without developing hypothyroidism complications 
like fatigue and other potentially life-threatening as myxe-
dema coma.32–34
Alternative schedules of sunitinib
Alternative schemes of sunitinib have been investigated in 
order to improve the safety profile and tolerance. Sunitinib 
37.5 mg once daily until PD and/or unacceptable toxicity 
were evaluated in an open-label, multicenter, phase II trial 
in which patients were randomized in a ratio of 1:1 in order 
to receive the mentioned dose in the morning or in the eve-
ning.35 The results of this trial in terms of both efficacy and 
toxicity overlapped with the phase III patients, with a median 
PFS of 34 weeks (95% CI, 24–49) and a median OS of 107 
weeks (95% CI, 72 to not calculable). Consequently, sunitinib 
37.5 mg once daily could be considered as an alternative 
dosing strategy, although it has not been directly compared 
with standard scheme. Regarding the optimal condition in 
sunitinib intake, no major differences were found between 
morning and evening dosing. In both the cases, no drug 
accumulation was observed across cycles and effective drug 
concentration was achieved.
Sunitinib 50 mg/daily in a schedule of 2 weeks ON/1 
week OFF has been investigated in metastatic renal cell 
carcinoma. The RESTORE trial accrued 76 patients, and 
they were randomized to sunitinib 4 weeks ON/2 weeks OFF 
schedule or to the 2 weeks ON/1 week OFF regimen. The 
results of this trial demonstrated better toxicity profile and 
better compliance with the 2/1 schedule.36 A retrospective 
analysis with 249 patients concluded with similar results.37 
Even though this scheme has not been evaluated in GIST 
patients, it could be considered in some patients with poor 
tolerance to the conventional schedule.38
Response evaluation of sunitinib
One of the main concerns regarding GIST treatment is to 
define the best method to evaluate treatment response. Tar-
get therapies induce several radiologic changes not only in 
size lesions but also in lesion structure (that is, variations in 
density) and in the pattern of contrast enhancement of intra-
tumoral nodules. RECIST are exclusively based on changes 
in size lesions, and as a result the RECIST assessment could 
mislead the treatment response, for example, GIST lesions 
enlarge because of necrosis or cystic degeneration, but not 
because of true tumor progression.
Choi criteria combine both biologic response and tumor 
volume response, and they were described in order to improve 
the sensitivity and specificity of the RECIST in the afore-
mentioned setting.39 No prospective trials have compared 
RECIST and Choi criteria, but Choi criteria seem to be less 
robust than in first-line setting with imatinib. Prospective–
retrospective series with small number of patients have failed 
in demonstrating superiority of Choi criteria in terms of 
better prediction of patient outcome depending on sunitinib 
response and even have recommended the RECIST.40–42
Surgery after sunitinib treatment
Unless treatment with sunitinib in metastatic GIST patients 
should be considered as palliative, a potentially radical sur-
gery could be occasionally planned in the clinical practice if 
the response has been good enough. Nonetheless, the scien-
tific evidence supporting this surgical management is very 
scarce. Two retrospective series with a very limited number 
of patients (10 and 50) suggest that post-sunitinib surgery 
is feasible, but the patients should be selected carefully 
because no clear improvement in terms of survival has been 
suggested. In addition, in the largest series, the surgery was 
frequently incomplete (not clearly related with the magnitude 
of the previous sunitinib response) and significant complica-
tions occurred in .50% of patients.43,44
Sunitinib rechallenge
The current approved treatment in advanced GIST after 
sunitinib failure is regorafenib based on data obtained in the 
pivotal phase III trial (the GRID trial).45 However, systemic 
treatment options are limited and the rechallenge with ima-
tinib and/or sunitinib emerges as a possibility in the daily 
practice. No trials have been designed in order to assess 
the efficacy of sunitinib rechallenge. The limited evidence 
comes from the report of 2 cases in whom prolonged clinical 
and radiological benefit was achieved after the rechallenge. 
Both the cases previously presented PR to sunitinib that 
lasted for .2 years and the primary tumor was located in 
stomach.46 In a post hoc analysis of the expanded use pro-
gram, those patients who had progressed to sunitinib and 
did not discontinue the therapy presented better outcomes 
than those who discontinued, suggesting a potential benefit 
of sunitinib beyond progression.30
Sunitinib or imatinib escalation treatment 
after first-line imatinib failure
At present, the best choice in second line is still unclear, 
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to sunitinib widely used options. A formal prospective 
comparison of both the strategies as a first approach in 
patients with GIST that progress after a first-line therapy with 
imatinb at 400 mg. A large retrospective analysis from the 
MetaGIST group proved that a dose escalation to 800 mg/day 
at the time of progression on first-line imatinib 400 mg/day 
was associated with new disease stabilization in ~30% 
of cases.47 Unfortunately, these stabilizations are often of 
limited duration. Although dose escalation is widely rec-
ommended within clinical guidance documents, the current 
evidence for its effectiveness in GIST after progression at 
the standard imatinib dose is based only on the analysis of 
several sets of observational data.
A retrospective series of 123 patients with KIT exon 11 
mutated GIST who progressed after first-line imatinib 400 mg 
showed a TTP of 10 months (95% CI 9.7–10.9) in the group 
of patients treated with sunitinib in comparison with 5 months 
in those receiving high doses of imatinib (95% CI 3.6–6.7) 
(P=0.012). No difference was found in OS (P=0.883). In 
imatinib arm, KIT exon 11 deletions were associated with 
a shorter TTP (7 vs 17 months; P=0.02), with a trend in OS 
(54 vs 71 months; P=0.063). No difference was found in 
patients treated with sunitinib (P=0.370).48 These results 
suggest that some GIST patients harboring KIT exon 11 
deletions may acquire secondary mutations more resistant 
to escalated dose of imatinib than to sunitinib. On the basis 
of these results, sunitinib as second-line treatment may be 
mostly considered in patients with KIT exon 11 deletion 
after imatinib being failure. However, validation in prospec-
tive studies on larger series of patients would be of great 
interest.
Nevertheless, two additional retrospective studies did not 
show differences in benefit between imatinib dose escalation 
and switching to sunitinib in second-line therapy of GIST 
(Hsu et al, 2014; Hislop, 2012).49,50 In these studies, however, 
mutational status was not analyzed. In the absence of pro-
spective comparative trials, imatinib escalation and switch to 
sunitinib are both acceptable options after imatinib failure. 
Physicians can choose either treatment considering the spe-
cific kinase mutations or distinct adverse events associated 
with the two treatments.
Mechanisms of sunitinib resistance
The mechanisms of sunitinib resistance are still under inves-
tigation, but some hypotheses have been established in cell 
line studies. Long-term exposure of sunitinib could induce 
methylation of the promoter of phosphatase and tensin 
homolog deleted on chromosome ten (PTEN) gene, which 
encodes the negative regulator of PI3K. The epigenetic 
silencing of PTEN could elicit a constitutive activation of 
the PI3K-AKT-mTOR pathway, one of the sunitinib targets 
as it has been previously mentioned.51
Sunitinib mainly blocks the autoactivation of KIT 
because it binds to the adenosine triphosphate (ATP)-binding 
pocket of the unactivated conformation of KIT. A shift in 
the equilibrium of activated/inactivated form of KIT toward 
the active conformation in which sunitinib is less effective 
has been postulated as a potential mechanism of sunitinib 
resistance.52
Similar to imatinib resistance, preclinical studies suggest 
that long exposure to sunitinib elicits the appearance of new 
mutations in the KIT activation loop conferring this resis-
tance to sunitinib (mainly in exon 17, for example, D816V, 
D816F, and T670I).53,54
Patient selection for sunitinib 
therapy
No predictive biomarkers of sunitinib response have been 
validated, although several putative clinical and molecular 
parameters have been studied in order to be useful in the 
selection of appropriate candidates for this therapy and avoid-
ing exposure to it in patients in whom the treatment will be 
ineffective. Some of them would be pre-treatment predictive 
markers of response, whereas other would be early markers 
of resistance or benefit when the therapy has been started.
Arterial hypertension and other clinical 
biomarkers
AH can be considered an on-target AE due to the inhibition 
of VEGFR caused by sunitinib. Activation of VEGFR-2 by 
vascular endothelial growth factor (VEGF) induces hypoten-
sion and vasodilatory effects in vascular endothelial cells. 
As a consequence, the inhibition of VEGFR-2 and VEGF 
interaction by sunitinib increases the peripheral vascular 
resistance. The molecular mechanisms of this effect include 
apoptosis of endothelial cells, reduction of nitric oxide 
levels (a vasodilator) and activation of a constrictor pathway 
endothelin-1.26
In renal cell carcinoma, AH experienced during sunitinib 
treatment has been related to better patient outcome.55,56 
Whether AH related to sunitinib in GIST patients can be 
used as biomarker has also been assessed. In a prospective 
series of 137 patients, the AH appearance of any grade was 
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Sunitinib in GiST treatment
OS (HR 0.2056, P=0.000).57 Another retrospective series 
of .1,000 patients included in the phase I/II and III and in the 
expanded use program also correlated AH of any grade with 
overall response (16% versus 3%, P=0.004), PFS (34 weeks 
versus 16 weeks, 95% CI, P,0.0001) and OS (87 weeks 
versus 53 weeks, 95% CI, P=0.0003).26
Regarding other potential clinic biomarkers, a subgroup 
analysis of the phase III trial revealed the benefit of sunitinib 
in terms of TTP regardless of age (,65 or contrary), ECOG 
(0 or 1) and previous imatinib exposure (.6 months or the 
contrary).19
imatinib intolerance
Although imatinib toxicity profile is in general accept-
able, ~4% of patients are intolerant to imatinib and discon-
tinuation is required. The major evidence of the efficacy 
of sunitinib in this setting comes from the phase III trial 
in which 13 patients enrolled were considered as imatinib 
intolerants. Nine of 13 patients were randomized to sunitinib, 
and 8 of them showed clinical benefit to sunitinib (4 PRs 
were observed) and only 1 patient experienced PD. These 
results emerge the possibility of better efficacy of sunitinib 
in first-line scenario, but further studies are required because 
number of patients evaluated was very few.19
imaging biomarkers
FDG-PET could be a potential and feasible tool for early 
sunitinib response assessment. A small study with 23 patients 
evaluated the maximal standardized uptake value (SUV) 
before and after the first 4 weeks of sunitinib therapy. 
Changes in SUV value were clearly related to PFS, specifi-
cally, basal SUV reductions of .25% were correlated with 
a PFS of 29 weeks, in contrast to those patients whose SUV 
did not reduce at least a 25% in whom PFS was ~4 weeks.58 
In addition, it seems that early SUV reductions of at least 25% 
in FDG-PET performed earlier at day 7 of cycle 1 of suni-
tinib correlate with treatment responses months earlier than 
could be appreciated with CT scan. These data come from 
the phase I trial in Western population, in which ~85%–89% 
of patients with clinical benefit of sunitinib (PR or SD) 
showed early metabolic response.17
Nonetheless, it is important to consider that GIST lesions 
can be negative in FDG-PET due to the small diameter 
(between 1 and 5 cm) or to the histological tumor changes 
(necrosis, myxoid degeneration, or scarring).59 However, this 
approach would require further validation in order to be used 
to routinely modify patient management.
Mutational status
Refractory GIST is a heterogeneous disease composed of a 
mixture of clones; each of them harbors different mutations 
mainly in KIT or PDGFRA. Despite every lesion in a given 
patient has the primary GIST mutation (except of wild-type 
GIST), secondary mutations can appear under treatment 
pressure and confer resistance to therapies. The percentage 
of secondary mutations in GIST with primary mutations is 
estimated to range between 44% and 90%, depending on the 
sensitivity of the method used to determine them. In addition, 
the development of several secondary mutations at the same 
time seems to be a common event.60 After imatinib exposure, 
secondary mutations are more commonly found in GIST with 
primary KIT exon 11 mutations than in GIST with primary 
KIT exon 9 mutations and not found in GIST wild-type. 
Secondary mutations after imatinib treatment are usually 
located at exons 13 (for example, V654A mutation) and 14 
(for example, T607I mutation), both encode the ATP-binding 
pocket, or in exon 17 (encodes kinase activation loop).61
The potential role of primary and secondary mutations as 
predictor factors of sunitinib response has been investigated. 
A retrospective analysis using samples from patients who are 
included in a phase I/II sunitinib trial (17) concluded that 
patients with KIT exon 9 mutations clearly benefited more of 
sunitinib than those patients who harbor KIT exon 11 muta-
tions in terms of objective response rate (37% versus 5%; 
P=0.002), PFS (19.4 months versus 5.1 months; P=0.0005), 
and OS (26.9 months versus 12.3 months; P=0.012).61 These 
results have also been reported in a series of 137 patients 
in whose tumors carried a KIT exon 9 mutations or were 
wild-type and presented clearly better 1-year PFS com-
pared with those whose tumors carried a KIT exon 11 or 
PDGFRA mutations (68% and 57% versus 34% and 15%, 
respectively).57 KITAY502-3ins mutations at exon 9 is the most 
sensitive to sunitinib.53
Regarding secondary mutations, in vitro studies with GIST 
cell lines suggest that sunitinib is highly active against kinase 
activity of KIT containing secondary mutations at ATP-
binding pocket (exons 13 and 14), in contrast to GIST cell 
lines harboring imatinib resistant mutations at activation loop 
(exons 17, for example, D820Y, D820E and NK822K, and 
exon 18).61,62 These findings correlate with better PFS and OS 
of patients treated with sunitinib with exon 13 and 14 muta-
tions, compared with patients with exon 17 and 18 mutations, 
although these results should be further validated.
The 10%–15% of GIST patients defined as “wild-type” 
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interest, since the vast majority do not respond to imatinib. 
In these cases, the deficiency of succinate dehydrogenase 
(due to either inactivating mutations or through epigenetic 
mechanisms)63 and sporadic mutations in the MAPK pathway 
have a major a role in tumor development.64 Among pediatric 
population, GIST WT is the most frequently found, sporadi-
cally or as a part of congenital syndromes such as Carneid triad 
or Neurofibromatosis type I. In this subset of patients, sunitinib 
shows promising substantial antitumor activity and acceptable 
tolerability.65 In addition, preclinical data suggest higher anti-
tumor efficacy of sunitinib compared with imatinib.66
Circulating biomarkers
Circulating plasma levels of the extracellular domain of 
soluble KIT (sKIT) have been evaluated as potential bio-
marker in patients enrolled in the phase III trial of sunitinib 
versus placebo. sKIT level reduction from the baseline was 
a significant predictor of time to tumor progression.67 How-
ever, this finding deserves further evaluation because sKIT 
changes could also be related to changes in KIT synthesis 
or metabolism, or even changes that sunitinib could elicit in 
the sKIT in non-neoplastic cells.68
The plasma levels of different isoforms of soluble vas-
cular endothelial growth factor receptor (sVEGFR) have 
been correlated with the outcome during sunitinib therapy. 
sVEGFR3 showed to have the greatest predictive potential 
for OS.69
New perspectives
Sunitinib has demonstrated efficacy against advanced GIST 
after imatinib progression and an acceptable toxicity profile. 
Currently, it is considered the standard second-line treat-
ment in metastatic GIST after progression or intolerance to 
imatinib. However, there are still several open questions that 
would help to better select the candidates for this treatment. 
Further investigation that could correlate GIST genotype with 
sunitinib response is necessary probably because mutational 
status seems to be the most promising potential biomarker. 
Therefore, determination of GIST genotype to help the 
optimal selection of therapy should be considered manda-
tory. Moreover, the repetition of the mutational analysis 
with new diagnostic tool such as liquid biopsy, if feasible, 
after disease progression, may be an option in the future that 
allows identification of secondary mutations or other altera-
tions, choosing the best therapeutic options in accordance 
with their sensitivity to TKIs.
Furthermore, the deep knowledge of mechanism of 
sunitinib resistance represents an unmet need. Apart from 
developing new therapies, the study of molecular events 
that occur at sunitinib progression could facilitate potentially 
effective drug combinations.
Disclosure
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